toggle visibility Search & Display Options

Select All    Deselect All
 |   | 
Details
   print
  Record Links
Author (up) Keating, G.M. url  openurl
  Title Posaconazole Type Journal Article
  Year 2005 Publication Drugs Abbreviated Journal Drugs  
  Volume 65 Issue 11 Pages 1553-67; discussion 1568-9  
  Keywords Animals; Antifungal Agents/administration & dosage/adverse effects/pharmacokinetics/pharmacology/*therapeutic use; Clinical Trials as Topic; Fungi/drug effects; Humans; Mycoses/*drug therapy/microbiology; Triazoles/administration & dosage/adverse effects/pharmacokinetics/pharmacology/*therapeutic use  
  Abstract Posaconazole is a triazole antifungal agent, administered as an oral suspension, with an extended spectrum of in vitro activity. Posaconazole 800 mg/day demonstrated clinically relevant activity against a range of fungi in patients with invasive fungal infections who were refractory to, or intolerant of, other antifungal therapy in an open-label, multicentre, phase III study (330 patients received posaconazole and 279 patients served as external controls). In aspergillosis, the global response success rate at the end-of-therapy visit (primary endpoint) was significantly higher in posaconazole recipients than in external controls (42% vs 26%). Posaconazole was also associated with overall success rates of 54% in zygomycosis, 46% in fusariosis, 43% in Pseudallescheria infection, 80% in phaeohyphomycosis and 100% in histoplasmosis. Success rates were 48% in refractory candidiasis, 69% in refractory coccidioidomycosis, 48% in refractory cryptococcal infection and 82% in refractory chromoblastomycosis or mycetoma. Posaconazole also demonstrated potential in febrile neutropenia in an open-label phase II study (success rate of 81% 7 days after the end of treatment). In a noncomparative, multicentre, phase III study in patients with advanced HIV infection who had azole-refractory oropharyngeal and/or oesophageal candidiasis, posaconazole 400 or 800 mg/day resulted in a clinical response in 132 of 176 patients (75%). Oral posaconazole suspension was generally well tolerated in patients with invasive fungal infections, including patients who received treatment for >or=1 year.  
  Address Adis International Limited, Auckland, New Zealand. demail@adis.co.nz  
  Corporate Author Thesis  
  Publisher Place of Publication Editor  
  Language English Summary Language Original Title  
  Series Editor Series Title Abbreviated Series Title  
  Series Volume Series Issue Edition  
  ISSN 0012-6667 ISBN Medium  
  Area Expedition Conference  
  Notes PMID:16033292 Approved no  
  Call Number refbase @ user @ Serial 23365  
Permanent link to this record
Select All    Deselect All
 |   | 
Details
   print

Save Citations:
Export Records: